✦ LIBER ✦

Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy

✍ Scribed by ERIC K DINER; MARSTON LINEHAN; MCCLELLAN WALTHER

Book ID: 108976904
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 145 KB
Volume: 12
Category: Article
ISSN: 0919-8172
DOI: 10.1111/j.1442-2042.2005.01193.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interleukin-2 dose, blood monocyte and C

Interleukin-2 dose, blood monocyte and CD25+lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma

✍ Gregers G. Hermann; Poul F. Geertsen; Hans von der Maase; Jesper Zeuthen 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 583 KB

Long-term complete response to very-low-

Long-term complete response to very-low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases

✍ Ken-ichi Harada; Hideaki Miyake; Toshifumi Kurahashi; Masato Fujisawa 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 333 KB

Correlation between steroid hormone rece

Correlation between steroid hormone receptors and response to medroxyprogesterone acetate therapy in renal cell carcinoma: results of a long-term study

✍ E. Bercovich; M. Cigno; M. Soli; R. Beghelli; F. Montanari; A. Martelli 📂 Article 📅 1989 🏛 Springer-Verlag 🌐 English ⚖ 482 KB

Prediction of response to combined immun

Prediction of response to combined immunotherapy with interferon-α and low-dose interleukin-2 in metastatic renal cell carcinoma: Expression patterns of potential molecular markers in radical nephrectomy specimens

✍ Hideaki Miyake; Iori Sakai; Mototsugu Muramaki; Toshifumi Kurahashi; Atsushi Tak 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

High-dose interleukin-2 for the treatmen

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006

✍ Jacob A. Klapper; Stephanie G. Downey; Franz O. Smith; James C. Yang; Marybeth S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

Thalidomide reduces serum C-reactive pro

Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy

✍ Igal Kedar; Wilmosh Mermershtain; Hefziba Ivgi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 341 KB

## Abstract Interleukin‐2 (IL‐2) has some antitumor activity in patients with renal cell carcinoma. It has been noted that response to IL‐2 and prognosis may be adversely affected by elevated serum levels of C‐reactive protein (CRP) or interleukin‐6 (IL‐6). We used thalidomide to treat patients wit